191 related articles for article (PubMed ID: 8615190)
1. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
Bordet R; Broly F; Destée A; Libersa C
Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190
[No Abstract] [Full Text] [Related]
2. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
[TBL] [Abstract][Full Text] [Related]
3. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
4. Association between the oxidative polymorphism and early onset of Parkinson's disease.
Agúndez JA; Jiménez-Jiménez FJ; Luengo A; Bernal ML; Molina JA; Ayuso L; Vázquez A; Parra J; Duarte J; Coria F
Clin Pharmacol Ther; 1995 Mar; 57(3):291-8. PubMed ID: 7697946
[TBL] [Abstract][Full Text] [Related]
5. Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism.
Landi MT; Ceroni M; Martignoni E; Bertazzi PA; Caporaso NE; Nappi G
Adv Neurol; 1996; 69():61-72. PubMed ID: 8615186
[No Abstract] [Full Text] [Related]
6. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
[TBL] [Abstract][Full Text] [Related]
7. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
Daly AK; Armstrong M; Monkman SC; Idle ME; Idle JR
Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
[TBL] [Abstract][Full Text] [Related]
8. Debrisoquine hydroxylase and Parkinson's disease.
Kondo I; Kanazawa I
Adv Neurol; 1993; 60():338-42. PubMed ID: 8420147
[TBL] [Abstract][Full Text] [Related]
9. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
[TBL] [Abstract][Full Text] [Related]
10. Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians.
Hadidi HF; Cholerton S; Monkman SC; Armstrong M; Irshaid YM; Rawashdeh NM; Daly AK; Idle JR
Pharmacogenetics; 1994 Jun; 4(3):159-61. PubMed ID: 7920696
[No Abstract] [Full Text] [Related]
11. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
[TBL] [Abstract][Full Text] [Related]
12. A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease.
Tsuneoka Y; Matsuo Y; Iwahashi K; Takeuchi H; Ichikawa Y
J Biochem; 1993 Aug; 114(2):263-6. PubMed ID: 7903297
[TBL] [Abstract][Full Text] [Related]
13. Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity.
Beyeler C; Daly AK; Armstrong M; Astbury C; Bird HA; Idle JR
J Rheumatol; 1994 Jun; 21(6):1034-9. PubMed ID: 7932410
[TBL] [Abstract][Full Text] [Related]
14. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
Douglas AM; Atchison BA; Somogyi AA; Drummer OH
Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
[No Abstract] [Full Text] [Related]
15. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6.
Wang SL; Huang JD; Lai MD; Liu BH; Lai ML
Clin Pharmacol Ther; 1993 Apr; 53(4):410-8. PubMed ID: 8097442
[TBL] [Abstract][Full Text] [Related]
16. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama.
Petersen DD; Kong AN; Jorge LF; Nebert DW; Arias TD
Pharmacogenetics; 1991 Dec; 1(3):136-42. PubMed ID: 1688244
[TBL] [Abstract][Full Text] [Related]
17. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
[TBL] [Abstract][Full Text] [Related]
18. Mutant debrisoquine hydroxylation genes in Parkinson's disease.
Armstrong M; Daly AK; Cholerton S; Bateman DN; Idle JR
Lancet; 1992 Apr; 339(8800):1017-8. PubMed ID: 1349052
[TBL] [Abstract][Full Text] [Related]
19. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
[TBL] [Abstract][Full Text] [Related]
20. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease.
Kurth MC; Kurth JH
Am J Med Genet; 1993 Oct; 48(3):166-8. PubMed ID: 8291573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]